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ABSTRACT 
 Obesity has become increasingly prevalent in the United States.  Bariatric surgeries have 
increased as the prevalence of obesity has risen, providing an effective alternative to weight loss. 
Intravenous acetaminophen (IVA) is a safe and effective non-opioid medication that can be 
given without the risk of respiratory or cardiac complications. Research has shown that the use of 
IVA during surgery can improve postoperative pain scores, reduce opioid requirements, and 
improve patient satisfaction.  
 A retrospective cohort study of 200 patients (100 per group) undergoing laparoscopic 
bariatric surgery (LBS) was performed. Statistical analysis was used to determine the 
relationship between those who received IVA near anesthesia induction or near end of surgery 
and intraoperative/postoperative opioid consumption and pain scores. Other study variables 
included: age, gender, American Society of Anesthesiologists (ASA) classification, Body Mass 
Index (BMI), and length of anesthesia (LOA). 
 The results of the study determined there was no significant relationship between the 
administration time of IVA and intraoperative/postoperative opioid consumption or pain scores. 
There were significant relationships found between IVA administration time and BMI, age, and 
LOA. 
 While no significant relationships were found related to the administration timing of IVA 
and opioid consumption and pain scores, many studies have found efficacy in the use of IVA in 
reducing opioid consumption and pain scores in a variety or procedures and populations. 
Although this study did not provide results influencing the administration timing of IVA, it is 
recommended that other studies follow a similar study design in further investigation into the use 
of IVA to enhance anesthesia care and improve patient safety. 
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OBJECTIVES 
 The primary objective of this study was to determine whether intravenous acetaminophen 
(IVA) should be given near anesthesia induction or near the end of surgery to optimize 
postoperative pain scores and minimize opioid consumption in patients undergoing laparoscopic 
bariatric surgery (LBS). The hypotheses for this study are: 
1. Patients who underwent LBS and received IVA within 30 minutes of anesthesia induction 
will have lower intraoperative opioid consumption compared to patients who received 
IVA within 30 minutes of end of surgery. 
2. Patients who underwent LBS and received IVA within 30 minutes of anesthesia induction 
will have lower postoperative opioid consumption compared to patients who received 
IVA within 30 minutes of end of surgery. 
3. Patients who underwent LBS and received IVA within 30 minutes of anesthesia induction 
will have lower postoperative pain scores compared to patients who received IVA within 
30 minutes of end of surgery. 
BACKGROUND 
 The Center for Disease Control (CDC) defines obesity as a body mass index (BMI) of 
greater than 30 in adults (CDC, 2016). Obesity is a growing concern for healthcare providers all 
over the world. One study reported that the prevalence of obesity in the United States was 
approximately 35% among men and women (Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, 
C. L., 2012). Obesity brings with it many comorbidities and risk factors for acute and chronic 
illness that can complicate the patient’s response to anesthesia.  
 Among the comorbidities seen in obese patients, physiologic changes of the neck and 
airway pose an increased threat to the safety of the patient during anesthesia care.  Increased 
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adipose tissue, particularly around the neck and oropharynx, can result in airway changes that 
limit the patient’s ability to breathe and limit the anesthesia provider’s access to the airway.  
Frequency of asthma and obstructive sleep apnea (OSA) in the obese patient are of serious 
concern due to the difficulty in manual and/or mechanical ventilation when the patient is lying 
flat and/or anesthetized (Thompson et al., 2011).  
 The prevalence of OSA in the obese population has been shown to be directly related to 
BMI.  A study of 290 patients preparing for weight loss surgery revealed that more than 70% of 
patients with a BMI from 31-94 had OSA (Lopez, P. P., M.D., Stefan, B., M.S., Schulman, C. I., 
M.D., & Byers, P. M., M.D., 2008). A meta-analysis studying the postoperative outcomes of 
patients with OSA showed that patients were more likely to experience oxygen desaturation, 
respiratory failure, and require intensive care during the postoperative recovery period (Kaw, R. 
et al., 2012). Due to the overwhelming difficulty of managing obesity as an illness many patients 
have found successful treatment with weight loss surgery/LBS. The American Society for 
Metabolic and LBS (ASMBS) reported that from the years 2011-2015 nearly 900,000 bariatric 
procedures were performed in the United States (ASMBS, 2016). A meta-analysis performed by 
Ribaric, G., Buchwald, J., & McGlennon, T. reported that LBS proved to be more effective than 
other weight loss strategies (Ribaric, G. et al., 2013).  
 In order to provide optimal patient outcome for those undergoing LBS adequate 
anesthesia depth and pain management are essential.  Anesthetic gases, opioids, and other 
adjunctive medications allow the anesthesia provider the greatest ability to maintain patient 
safety.  However, due to the common side effects of these medications, patients remain at risk 
for adverse effects. Opioids commonly result in a depressed respiratory drive and decreased 
mental alertness. A 2008 study showed that patients taking opioids were 67% more likely to 
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experience OSA (Farney, R. J., Walker, J. M., Boyle, K. M., Cloward, T. V., & Shilling, K. C., 
2008). During anesthesia induction, these complications can be managed effectively by 
performing laryngoscopy and tracheal intubation followed by mechanical ventilation.  The 
anesthesia provider can maintain airway protection during the intraoperative period in the same 
manner and manage pain by administering opioids and other analgesics. 
 Airway protection has become the greatest concern for the care of obese patients during 
the emergence of anesthesia (Greenwood, 2017).  As patients emerge from anesthesia they 
become aware of their surgical pain and pain management becomes of particular concern.  Pain 
management in the immediate postoperative period requires a balance of the patient’s alertness 
and ability to breath spontaneously to maintain adequate ventilation. An imbalance of the 
patient’s respiratory ability and analgesic administration in these crucial minutes after surgery 
can result in respiratory distress/failure, cardiac depression, and even death. These serious 
adverse effects can be due to an over-sedation effect (respiratory failure/cardiac depression) that 
result in airway obstruction or a hyper-stimulatory effect that comes as a result of inadequate 
pain control. A systematic review of more than 8,000 patients revealed that, in all included 
studies, opioid administration resulted in an increase incidence of upper airway obstruction. This 
review further showed that in many cases opioid administration correlated with decreased 
respiratory compliance and airway reflexes (Ehsan, Z., Mahmoud, M., Shott, S. R., Amin, R. S., 
& Ishman, S. L., 2016). 
 Obese patients commonly suffer from OSA and are difficult to maintain pain control. A 
study presented by the Journal of the American Society of Anesthesiologists reported that 
patients with OSA experienced increased pain as compared to patients without OSA (Doufas, A. 
G., Tian, L., Davies, M. F., & Warby, S. C., 2013). As obese patients have a significantly higher 
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prevalence of OSA we can conclude that obese patients will likely experience increased pain 
after surgery resulting in higher analgesic requirements.  The administration of opioids during 
the immediate postoperative period is of concern because it is the time when patients are the 
most vulnerable to respiratory depression. An effective opioid dose to treat pain may 
correspondingly be the dose that causes a depressed respiratory drive or decreased mental 
awareness leading to inadequate ventilation and hypoxemia. 
 The increased risk that comes from opioid administration in the immediate postoperative 
period leads the anesthesia provider to rely on multimodal therapies that enhance pain control 
and limit dangerous adverse effects.  IVA is a non-opioid analgesic that can be used to enhance 
pain management in the surgical patient. While the exact mechanism of action of IVA is 
unknown numerous studies have shown the efficacy of this medication as an analgesic. Singla et 
al., showed that IVA had a significantly shorter time to maximum concentration compared to 
oral or rectal acetaminophen resulting in a faster onset (Singla, NK., et al, 2012). The rapid onset 
of IVA is due to its 100% bioavailability.  The onset of action of IVA is approximately 15 
minutes after the start of infusion at a dose of 15mg/kg with a maximum single dose of 1 gram 
(age 13 years and greater) (Cadence Pharmaceuticals, a Mallinckrodt company, 2013). While 
IVA is contraindicated in patients with a hypersensitivity to acetaminophen and those with 
severe liver impairment, there are no reported adverse effects related to respiratory or cardiac 
systems. IVA, used in multimodal therapy, has the ability to effectively enhance pain control 
without increasing the risk of respiratory or cardiac depression.  Unlike oral or rectal 
acetaminophen, IVA does not undergo a first-pass hepatic effect which provides an increased 
bioavailability leading to more effective pain control (Cadence Pharmaceuticals, a Mallinckrodt 
company, 2013). 
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 The administration of IVA has been shown in numerous studies to be effective in 
improving postoperative pain scores. A study by Atashkhoyi, S., Rasouli, S., Fardiazar, Z., 
Ghojazadeh, M., & Hatami, M. P. (2014), showed that 100 patients undergoing cesarean section 
who received IVA 20 minutes before the end of surgery had significantly lower pain scores in 
the post anesthesia care unit (PACU) (Atashhoyi et al., 2014).  A study of 60 patients showed 
significantly lower pain scores in cesarean section patients who received IVA 20 minutes 
preoperatively (Ayatollahi, V., Faghihi, S., Behdad, S., Heiranizadeh, N., & Baghianimoghadam, 
B, 2014). Another study found that in pediatric patients undergoing inguinal hernia repair 
likewise showed significantly less pain scores in those who received IVA compared to the 
placebo group (Kahlili et al., 2016). A 2014 study of patient satisfaction after surgery showed 
that those receiving IVA reported a score of “excellent” (Apfel, C. C., Souza, K., Portillo, J., 
Dalal, P., & Bergese, S. D., 2014).  
 In addition to improved pain scores and patient satisfaction, IVA has been shown to 
decrease opioid consumption in the intraoperative and postoperative periods.  A retrospective 
study by Song, K., Melroy, M. J., & Whipple, O. C. (2014), showed that 104 patients undergoing 
LBS who received IVA intraoperatively required less morphine equivalents than the control 
group who received opioid therapy only. This is one of the limited studies of IVA given to 
patients undergoing LBS, and while it provides insight into the control of opioids related to this 
patient population it did not find a significant reduction in pain scores in this population (Song et 
al., 2014).  This evidence supports the proposed study in that administration of IVA near 
induction or EOS may be a factor in lowering pain scores in the postoperative period. A 2009 
study of 90 women undergoing abdominal hysterectomy showed that those who got IVA 30 
minutes before induction had lower postoperative pain scores and lower opioid requirements 
INTRAOPERATIVE ADMINISTRATION OF IV ACETAMINOPHEN
   
10 
than those who received IVA 30 minutes before EOS (Arici, S., Gurbet, A., Türker, G., 
Yavaşcaoğlu, B., & Sahin, S., 2009).  This is one of the limited studies providing information 
related to the difference in administration of IVA near induction or EOS.  The study by Arici, et 
al. in contrast to the study by Song, et al. supports the need for further investigation into the use 
of IVA in patients undergoing LBS as it relates to administration timing. Jelacic et al. (2016), 
showed that patients who underwent cardiac surgery used significantly less opioids compared to 
the placebo group in the first 24 hours postoperatively after receiving IVA intraoperatively but 
did not show a significant difference in pain scores between the two groups. (Jelacic et al., 2016). 
A 2015 study of 92 patients who underwent LBS showed a nearly 40% decreased in opioid 
requirements after having received IVA intraoperatively (Gonzalez, A. M., Romero, R. J., Ojeda-
Vaz, M. M., & Rabaza, J. R., 2015).   
 These studies provide a good foundation of efficacy for the use of IVA in surgical 
patients.  However, the limited information related to the use of IVA in reducing opioid 
consumption and pain scores in patients undergoing LBS supports the need for further 
investigation into this important patient population. 
METHODOLGY 
Design 
 The design for this study is a cross-sectional cohort.  The cross-sectional study design 
allows for the easy retrieval of patient data and case characteristics that were used to study the 
relationships related to the use of IVA in patients undergoing laparoscopic bariatric procedures.  
Sample 
 CAMC is a tertiary referral center located in Charleston, West Virginia.  There are three 
main hospitals in the Charleston area: General, Memorial, and Women and Children’s Hospitals. 
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The CAMC health system performs more than 45,000 operating room procedures each year.   
The CAMC General Hospital performs bariatric surgical procedures, has a dedicated bariatric 
unit, and an associated Weight Loss Center (CAMC, 2017) (CAMCa, 2017) (CAMCb, 2017). 
 A chart review was performed on patients who underwent laparoscopic bariatric surgical 
procedures at the General Hospital between January 1, 2007 and April 1, 2017. Two study 
groups were compared as they relate to total intraoperative opioid consumption, total opioid 
consumption during the first two hours of anesthesia recovery, pain scores recorded within 5 
minutes of arrival in the post anesthesia care unit (PACU), and pain scores recorded at 1 hour 
after arrival in the PACU. 
 The International Classification of Diseases, 9th and 10th revisions, Clinical Modification 
ICD-9-CM and [ICD-10-CM] codes 44.38 [0D16479, 0D1647A, 0D164J9, 0D164JA, 0D164K9, 
0D164KA, 0D164Z9, 0D164ZA] (Roux-en-Y gastric bypass, proximal/distal), 43.89 
[ODB63ZZ], (unlisted laparoscopy, stomach), 44.95 [0DV64CZ] (Implantation of adjustable 
gastric band) 44.82 [0DB64Z3] (Laparoscopy, sleeve gastrectomy) 44.96 [0DW64CZ] 
(Replacement and revision of gastric band and port) were used for identification of patient 
records that were included in the study. 
• Inclusion criteria consisted of patient’s age 18-65 years, American Society of 
Anesthesiologists (ASA) classification of II-III, who underwent LBS lasting 
between 60 and 180 minutes, and received IVA within 30 minutes of induction or 
within 30 minutes of EOS.  
• Exclusion criteria consisted of patients outside ages 18-65; outside ASA 
classification II-III; allergy to acetaminophen; history of: liver disease, opioid 
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abuse, chronic pain, current use of opioids for acute/chronic pain; patients who 
underwent open LBS; patients who underwent LBS and did not receive IVA or 
did not receive IVA within 30 minutes of induction or end of surgery (EOS). 
Procedures/Protocol 
 A retrospective study was performed using patient information gathered from the CAMC 
EMR system for patients who underwent LBS. A sample of 200 patients who underwent 
laparoscopic bariatric surgical procedures and received IVA were selected for this study and 
assigned to one of two groups for comparison. The first group included 100 patients who 
underwent LBS and received IVA within 30 minutes of anesthesia induction. The second group 
included 100 patients who underwent LBS and received IVA within 30 minutes of EOS.  
 Age was assessed based on years of life upon hospital admission on the day surgery.  
Gender was based on the gender recorded and/or reported by patient as indicated on the patient 
record. ASA classification was assigned based on the pre-anesthesia assessment performed by an 
anesthesiologist. BMI was calculated based on patient height and weight as recorded in the pre-
anesthesia assessment and was used to assess for obesity. Length of anesthesia (LOA) is defined 
as the time between anesthesia start time and anesthesia end time. Pain scores were based on the 
assessment of PACU nurses and total postoperative opioid consumption will be based on the 
total opioids given in the first 90 minutes in the PACU. Opioid consumption refers to the total 
opioid amount measured in milligrams (mg) or micrograms (mcg) administered to the patient 
and will include any opioids given during the preoperative, intraoperative, or postoperative 
periods.  All opioids were converted to morphine equivalents for calculation and comparison 
between groups.   
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Data Analysis 
 Data collected from the CAMC EMR system was analyzed as it relates to the primary 
objective of the research study.  The dependent variables include: total opioid consumption 
during the intraoperative, total opioid consumption during the postoperative period, and pain 
scores within 5 minutes of admission to PACU and at 1 hour after arrival in the PACU. The 
primary independent variable was whether IVA was administered within 30 minutes of 
anesthesia induction or 30 minutes of EOS. Secondary independent variables include: age, 
gender, ASA classification, BMI, and LOA. 
 An independent t-test was used to compare the two groups based on age, BMI, and LOA. 
A chi-square test was used to compare the two groups based on gender and ASA classification. 
A step-wise regression statistical analysis was used to determine the relationship between IVA 
administered within 30 minutes of anesthesia induction, IVA administered within 30 minutes of 
EOS, age, gender, BMI, ASA classification and LOA; and the total intraoperative opioid 
consumption, total postoperative opioid consumption, and pain scores on arrival in PACU and at 
1 hour after arrival into PACU.  A p-value of <.05 will determine statistical significance.  The 
data was analyzed using statistic analyzing software (SPSS). 
RESULTS 
 During January 2007 and April 2017, a group of 200 patients that met inclusion criteria 
were assigned to one of two groups based on the administration time of IVA in the intraoperative 
period.  Group 1 consisted of 100 patients who received IVA within 30 minutes of anesthesia 
induction.  Group 2 consisted of 100 patients who received IVA within 30 minutes of EOS.  
Statistical analysis was performed to compare these two groups based on age, BMI, LOA, 
gender, and ASA classification.  An independent t-test was performed to compare the study 
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groups based on age, BMI and LOS, and were found to have no significant differences. The two 
groups were similar related to age, BMI, and LOA with values of 0.499, 0.692, and 0.266, 
respectively (p>0.05) See Table 1.  A chi-square test was used to compare the two groups based 
on gender and ASA classification and was found to have no significant differences. The two 
groups were similar related gender and ASA classification with values of 0.849 and 0.617, 
respectively (p>0.5) [See Tables 2-3]. 
Table 1 
 IVGroup N Mean Std. Deviation Std. Error Mean 
Age (years) Induction 100 42.610 10.2414 1.0241 
End 100 43.640 11.2443 1.1244 
LOA (min) Induction 100 107.220 16.6027 1.6603 
End 100 104.510 17.7118 1.7712 
BMI Induction 100 47.2365 8.12251 .81225 
End 100 46.7628 8.74444 .87444 
 
Table 2 
 
Gender (M/F) 
Total F M 
IVGroup End Count 84 16 100 
Expected Count 83.5 16.5 100.0 
Std. Residual .1 -.1  
Induction Count 83 17 100 
Expected Count 83.5 16.5 100.0 
Std. Residual -.1 .1  
Total Count 167 33 200 
Expected Count 167.0 33.0 200.0 
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Table 3 
 
ASA2 
Total 0 1 
IVGroup End Count 75 25 100 
Expected Count 76.5 23.5 100.0 
Std. Residual -.2 .3  
Induction Count 78 22 100 
Expected Count 76.5 23.5 100.0 
Std. Residual .2 -.3  
Total Count 153 47 200 
Expected Count 153.0 47.0 200.0 
 
 
 Several step-wise regressions were performed to compare the two groups related to 
intraoperative/postoperative opioid consumption, and pain scores measured at within five 
minutes of arrival to PACU and after 1 hour of admission to PACU. This statistical analysis 
found no significant differences between the two groups as they relate to these variables. This 
analysis did however find some significant relationships among other values. 
 The first step-wise regression was to show the relationship between when the IVA was 
administered and the intraoperative opioid consumption.  The other independent variables, age, 
BMI, LOA, ASA classification, and gender, were also included.  The results of this analysis are 
given in Table 4.  There was no relationship between when the IVA was given and the amount of 
intraoperative opioid consumption.  This analysis did however reveal that patients with increased 
age received significantly less intraoperative opioids compared to others in the group with a 
value of -0.389 (p<0.5).  Furthermore, patients with an increased LOA received significantly 
higher intraoperative opioids with a value of 0.127 (p<0.5) [See Table 4]. 
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Table 4 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 47.300 3.173  14.909 .000 
Age (years) -.378 .071 -.352 -5.300 .000 
2 (Constant) 34.307 5.461  6.282 .000 
Age (years) -.389 .070 -.363 -5.544 .000 
LOA (min) .127 .044 .189 2.897 .004 
a. Dependent Variable: Opioid Total (intraop) 
 
  The second step-wise regression was to show the relationship between when the IVA 
was administered and the postoperative opioid consumption with other independent variables 
including: age, BMI, LOA, ASA classification, and gender.  The results of this analysis are given 
in Table 5.  There was no relationship between when the IVA was given and the total 
postoperative opioid consumption.  This analysis did reveal that patients with an increased age 
had significantly less opioid consumption compared to others in the group with a value of -0.121 
(p<0.5) [See Table 5]. 
Table 5 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 14.330 2.495  5.744 .000 
Age (years) -.121 .056 -.151 -2.150 .033 
a. Dependent Variable: Opioid Total (postop) 
 
 The third step-wise regression was to show the relationship between the IVA 
administration time and the pain score upon admission to PACU.  Other independent variables 
included age, BMI, LOA, ASA classification, and gender. There was no relationship found 
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between when the IVA was administered and the pain scores upon admission to PACU or any of 
the independent variables. 
 The fourth, and last, step-wise regression performed was to show the relationship 
between when the IVA was given and the pain scores recorded 1 hour after admission to PACU.  
Other independent variables included age, BMI, LOA, ASA classification, and gender. The 
results of this analysis are given in Table 6.  No relationship was found between when the IVA 
was given and the pain scores 1 hour after admission to PACU.  There were however some 
significant relationships related to BMI and LOA.  As BMI increased, the pain score recorded 1 
hour after admission to PACU was significantly decreased with a value of -0.180 (p<0.5).  In 
contrast, as LOA increased, the pain scores 1 hour after admission to PACU were also increased 
with a value of 0.067 (p<0.5) [See Table 6]. 
Table 6 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 11.805 2.885  4.092 .000 
BMI -.156 .060 -.180 -2.574 .011 
2 (Constant) 5.828 3.888  1.499 .135 
BMI -.180 .061 -.209 -2.967 .003 
LOA (min) .067 .030 .159 2.264 .025 
a. Dependent Variable: Pain Score (1hr) 
 
DISCUSSION 
 The purpose of this research study was to determine if administration timing of IVA in 
patients undergoing LBS had a significant relationship to the reduction of postoperative pain 
scores or a decrease in total opioid consumption.  The hypotheses of the study projected a 
significant decrease in both pain scores and intraoperative/postoperative opioid consumption. 
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The results of this study did not support any of the hypotheses as given. They did however, shed 
light on some important correlations as related to patient demographics and procedure 
characteristics such as age, BMI, and LOA.  While anesthesia providers may have no control 
over these variables the information gathered in this study can assist providers with more 
efficient knowledge and an improved practice plan as it relates to this important patient 
population. 
 The literature available related to the direct question of IVA administration timing is 
limited. In direct comparison, our study and the study performed by Arici et al. did not have 
correlating results.  Arici et al. showed that patients who received IVA within 30 minutes of 
induction of anesthesia had significantly less postoperative pain and used significantly less 
opioids. These results did correlate with the hypothesis of this study. However, the comparative 
was limited to patients undergoing abdominal hysterectomy and naturally one that is gender 
specific.  While our study gathered data on weight loss surgery, in general, there are multiple 
variations of these types of procedures that were included in the data collection. This could be 
one of the reasons the two studies did not have had correlating results.  Where the comparative 
only included females in their study, this study similarly, studied mostly females (167 compared 
to 33 males).  Overall, while our study compared to the study by Arici, et al. were constructed 
similarly the two studies differed mainly in the type of procedures performed (Arici et al., 2009).  
 While this study collected patient data based on a variety of LBS procedures it is 
expected that the variety of procedures did not have a significant impact on the results of the 
study.  Song, et al., reported that in a study comprised of over 100 patients undergoing various 
bariatric procedures the IVA groups had no significant difference in pain scores compared with 
the non-IVA groups included in the study (Song et al., 2014).  
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 This study found that the most significant characteristics related to postoperative pain and 
opioid consumption in patients undergoing LBS was age, BMI, and LOA.  These results are 
consistent with common practice methods related to opioid dosing and administration.  As opioid 
dosing is generally weight based in kilograms and administration is related to timing it is 
expected that patients with an increased BMI will have an increased opioid requirement 
compared to those with a lower BMI.  Similarly, since opioids are metabolized at a specific rate, 
dependent on the medication and the individual, it is expected that as the LOA is increased the 
total opioid consumption will also increase. This is based on the assumption that the provider 
desires to maintain the same amount of pain control during the entire procedure.  
 There are some increased risks to patient safety related to these results.  As discussed, the 
incidence of OSA in patients undergoing LBS is approximately 70% (Lopez, P. P., M.D., Stefan, 
B., M.S., Schulman, C. I., M.D., & Byers, P. M., M.D., 2008).  There are important risks 
associated with OSA that impact patient safety when opioids are administered.  Kaw et al., 2012 
revealed obese patients with OSA are more likely to require intensive care due to postoperative 
complications (Kaw, R. et al., 2012). In conjunction with an increased BMI, this patient 
population can expect a variable LOA which may increase these risks due to the increased opioid 
requirements as shown in this study. With an understanding that this high-risk patient population 
is shown to have increased opioid requirements; anesthesia providers should remain vigilant in 
recognizing patterns and taking precautions/preparations particularly during emergence and the 
postoperative period.   
 Due to the nature of this retrospective design a variety of limitations may have had an 
impact on the results of the study.  The practice of the anesthesia provider may be the factor with 
the largest impact.  While all of the data collected consisted of patients who had procedures at 
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the CAMC General Hospital, there are a variety of anesthesia providers involved in the care of 
these patients.  In addition to an inconsistent anesthetic plan due to a variety of providers, a 
generalized anesthetic plan related to the procedure and not the patient may have impacted the 
results of the study.   
 Other limitations as related to the patient population may have had an impact on the study 
results. The primary variable influencing this study was the presence of pain.  This variable 
influenced all analgesics (opioid and non-opioid) administered intraoperatively and 
postoperatively.  In the same regard, the only analgesics included in the study were opioid based 
analgesics and therefore may have impacted each of the primary results when the patient 
received a non-opioid analgesic either intraoperative or postoperatively.   
 While comprehensive inclusion/exclusion criteria were used to select optimal groups for 
this study design, it is possible that the histories as reported by the patient or collected by the 
provider were inconsistent or incomplete.  Furthermore, relating to the assessment of pain scores, 
each provider may have inconsistent assessment methods compared to another provider.  In the 
same manner, each patient may interpret their pain differently than another patient in the same 
situation. Each of these factors may have influenced both the pain scores and total opioid 
consumption in the postoperative periods.   
 While some limitations exist, there are some important factors that strengthen this study 
as a whole.  The study design was appropriate for the purpose of the objectives. Furthermore, 
this study design is applicable to any institution that provides similar services and can therefore 
apply the information as appropriate.  Each patient in either group met comprehensive 
inclusion/exclusion criteria. These aspects yielded two study groups that were not significantly 
different.  The data collected was from procedures performed at the same facility and while there 
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are many procedures performed here each year, the surgeons operating in this facility is limited. 
The majority of the data collected of the 200 patient records had only two surgeons who 
performed the operation.  These factors provide consistency in the procedures performed and 
limits the variability that could influence the study results.  
RECOMMENDATIONS 
 This study was designed to contribute to the current literature by providing additional 
insight as to the administration time of IVA in patients undergoing LBS.  The results of this 
study showed that there was no significant relationship between the two groups as they relate to 
intraoperative/postoperative opioid consumption and postoperative pain scores.  While no 
significant relationship was found in this study, other studies conducted in a similar fashion 
involving the use of IVA may yield additional information.  It is recommended that the 
application of this study design, particularly related to the administration timing of IVA, be used 
in a variety of patient populations and a variety of procedures to further understand the use of 
IVA and its ability as a non-opioid analgesic.  Additionally, any study involving patients with an 
increased BMI and the use of IVA may yield constructive information to assist in maintaining 
patient safety in this high-risk population. 
CONCLUSION 
 The primary objective of this study was to determine the relationship of the 
administration timing of IVA and intraoperative/postoperative opioid consumption and 
postoperative pain scores.  It was hypothesized that the early administration of IVA would result 
in an overall decrease in both opioid consumption and pain scores. However, the results of this 
study showed that there was no significant relationship between these factors.  While patients 
with an increased BMI undergoing LBS are at an increased risk for complications, the 
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administration timing of IVA may not have a direct impact on reducing these risks. Other studies 
have shown efficacy in using IVA to reduce pain scores and opioid consumption. Therefore, IVA 
should be regularly considered as an effective adjunct to opioid analgesia when creating an 
anesthetic plan.  The application of these principles will assist the anesthesia provider in 
providing optimal care for each patient and increase overall patient safety.  
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